European Antibody Congress 2012
27 - 28 November 2012,
Starling Geneva Hotel & Conference Center, Geneva, Switzerland
Discover. Develop. Get to market.
The 8th annual European Antibody Congress is Europe’s leading forum for antibody discovery, development and partnering.
The European Antibody Congress is now 3-congresses in one in 2012, combining the very best of mAb discovery and development with the next generation of Bispecific and Multivalents and Antibody Drug Conjugates.
Showcasing major global trends, recent intra-market clinical progress, best practice and 1-2-1 partnering opportunities, this event delivers unrivalled industry participation across the antibody value chain.
Sponsors
Gold Sponsor
Silver Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
What sets European Antibody Congress apart:
- Real peer to peer intelligence: an 85% governmental, pharma and biotech speaker faculty delivers on content
- Diverse content: 3 tracks covering the future of antibody and antibody alternatives
- Quality and quantity: over 80 keynotes, case studies, panels and streams offering a comprehensive programme to match your business needs
- Meet active decision makers: congress attendees are vetted on their responsibilities to managing manufacturing campaigns, brands, business units and pipelines
- A truly global gathering: all major regions and continents represented with over 30 countries in attendance
- 2hrs of immersive social events: have the means to network with the industry’s elite
3 tracks offering you greater choice of your interest or discipline
Monoclonal antibody track
- Structure-function relationships
- Improving efficacy and drugability of mAbs
- Antibody epitope mapping
- Discovery of novel targets for mAb therapy
- Antibody successes and attrition rates
- From the bench to recent marketing authorisation
- Generation and identification of mAbs against new targets
Antibody drug conjugate track
- Applications for bispecifics in emerging classes
- Robust rationales for target selection
- Advancement of bispecific candidate through the clinic
- Flexible platforms for different targets
- Clinical trial design and regulatory requirements
- Strategies for avoiding immunogenicity
- Improve expression process development strategies
Bispecific and alternative protein track
- Antibody engineering strategies to optimize ADC performance
- Latest clinical trial performances
- Strategies in ADC bioprocessing, handling and charactersation
- Clinical and preclinical guidance on drug PK and metabolism
- Cutting edge linker and payload platforms
- Innovations in target selection, drug delivery & MOA
- Partnering & licensing, drug marketing & reimbursement
Who should attend:
- Pharmaceutical Manufacturers
- Biotechs
- Government / Regulatory Bodies
- Academia / Research Institutes
- Contract Service Organisations (CMO and CSO)
- Equipment Manufacturers & Technology Providers
- Venture Capitalists
- Legal Firms
- Consultants
Who should sponsor:
- Pharma / Biotechs
- Contract Research Organisations
- Contract Manufacturing Organisations
- Platform Technology Providers
- Drug Delivery / Drug Diagnostic Providers
- Medical Device Manufacturers
- OEM / Equipment Providers
- Delivery / Discovery Platforms
- Venture Capitalists
- Law Firms
- Consultants
Sponsors
Gold Sponsor
Silver Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
Associate Sponsor
